
ENTA
Healthcare · Biotechnology · $320.1M market cap
$10.99-0.21 (-1.9%)Nov 13, 4:26 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -14.4% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2026 · upcoming | After the close | -0.82 | — | — |
| Aug 10, 2026 | After the close | -0.37 | -0.67 | -81.1% |
| May 11, 2026 | After the close | -0.57 | -0.45 | +21.1% |
| Feb 9, 2026 | After the close | -0.88 | -0.42 | +52.3% |
| Nov 17, 2025 | After the close | -1.01 | -0.87 | +13.9% |
| Aug 11, 2025 | After the close | -0.88 | -0.85 | +3.4% |
| May 12, 2025 | After the close | -1.14 | -1.06 | +7.0% |
| Feb 10, 2025 | After the close | -1.35 | -1.05 | +22.2% |
| Nov 25, 2024 | After the close | -0.92 | -1.36 | -47.8% |
| Aug 5, 2024 | After the close | -1.41 | -1.07 | +24.1% |
| May 6, 2024 | After the close | -1.40 | -1.47 | -5.0% |
| Feb 7, 2024 | After the close | -1.23 | -1.58 | -28.5% |
| Nov 20, 2023 | After the close | -2.21 | -1.33 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus;…
| +39.8% |
| Aug 7, 2023 | After the close | -2.19 | -1.86 | +15.1% |
| May 8, 2023 | After the close | -1.93 | -1.79 | +7.3% |
| Feb 7, 2023 | After the close | -1.60 | -1.39 | +13.1% |
| Nov 21, 2022 | After the close | -1.35 | -1.27 | +5.9% |
| Aug 8, 2022 | After the close | -1.39 | -1.53 | -10.1% |
| May 9, 2022 | After the close | -1.41 | -1.63 | -15.6% |
| Feb 8, 2022 | After the close | -1.11 | -1.48 | -33.3% |
| Nov 22, 2021 | After the close | -1.19 | -1.22 | -2.5% |
| Aug 5, 2021 | After the close | -1.29 | -1.19 | +7.8% |
| May 6, 2021 | After the close | -0.97 | -1.09 | -12.4% |
| Feb 8, 2021 | After the close | -0.77 | -0.41 | +46.8% |
| Nov 23, 2020 | After the close | -0.97 | -1.46 | -50.5% |
| Aug 4, 2020 | After the close | -0.96 | -0.71 | +26.0% |
| May 6, 2020 | After the close | -0.72 | -0.30 | +58.3% |
| Feb 6, 2020 | After the close | 0.60 | 0.65 | +8.3% |
| Nov 21, 2019 | After the close | 0.56 | 0.44 | -21.4% |
| Aug 6, 2019 | After the close | 0.17 | 0.33 | +94.1% |
| May 7, 2019 | After the close | -0.05 | 0.20 | +500.0% |
| Feb 6, 2019 | After the close | 1.29 | 1.25 | -3.1% |
| Nov 26, 2018 | After the close | 1.19 | 1.30 | +9.2% |
| Aug 7, 2018 | After the close | 0.90 | 0.97 | +7.8% |
| May 8, 2018 | After the close | 0.25 | 0.61 | +144.0% |
| Feb 7, 2018 | After the close | 0.27 | 0.40 | +48.1% |